Jump Financial’s Unity Biotechnology UBX Stock Holding History

Jump Financial’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,370	Closed	-$156K	–	1515
2021 Q2	$156K	Buy	+3,370	New	+$162K	0.02%	923

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Jump Financial's UBX Position: Q3 2021 in Review

Jump Financial sold out of Unity Biotechnology (UBX) in Q3 2021, closing a stake of 3,370 shares — an estimated $156K sold.

Jump Financial first reported a position in UBX in Q2 2021 and held it in 1 quarter. The position peaked at $156K in Q2 2021. 84 funds tracked by Wall St. Rank hold UBX as of Q3 2021.

Jump Financial reported no remaining Unity Biotechnology position as of Q3 2021 after selling out during the quarter.
Jump Financial sold 3,370 Unity Biotechnology shares in Q3 2021, an estimated $156K.
Jump Financial first reported a position in Unity Biotechnology in Q2 2021 and held it in 1 quarter.
Jump Financial's Unity Biotechnology position peaked at $156K in Q2 2021.
84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2021.

Based on Jump Financial's 13F filing for Q3 2021, filed 12 Nov 2021.